Valuation Unicycive Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 21:00:00 16/10/2026 BST			5-day change	1st Jan Change
3.360 ^USD	-6.41%		-18.25%	-41.77%

10-01	Unicycive Therapeutics, Inc. Appoints Meredith Manning to its Board of Directors, Each of the Audit, Compensation, and Nominating and Corporate Governance Committees, and Chairperson of the Nominating and Corporate Governance Committee	CI
09-29	Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	30.84	8.148	30.16	82.44	124	93.59	-	-
Change	-	-73.58%	270.11%	173.36%	50.43%	-24.52%	-	-
Enterprise Value (EV)	30.84	8.148	30.16	82.44	124	93.59	93.59	93.59
Change	-	-73.58%	270.11%	173.36%	50.43%	-24.52%	0%	0%
P/E	-2.4x	-0.45x	-0.68x	-1.42x	-3.46x	-2.65x	1.83x	0.39x
PBR	-	-	-	-	-	-	-	-
PEG	-	-0x	-0.1x	0x	0x	0.1x	-0x	0x
Capitalization / Revenue	-	8.57x	44.7x	-	-	68.3x	0.63x	0.17x
EV / Revenue	-	0x	0x	-	-	68.3x	0.63x	0.17x
EV / EBITDA	-	-	-	-	-	-	-	-
EV / EBIT	-0x	-0x	-0x	-0x	-0x	-2.46x	1.57x	0.25x
EV / FCF	-0x	-	-0x	-0x	-0x	-2.87x	-4.52x	0.62x
FCF Yield	-18.8%	-	-60.7%	-34.8%	-25.3%	-34.8%	-22.1%	162%
Dividend per Share ²	-	-	-	-	-	-	2.08	5.37
Rate of return	-	-	-	-	-	-	61.9%	160%
EPS ²	-8.6	-12	-12.8	-5.6	-1.67	-1.266	1.834	8.595
Distribution rate	-	-	-	-	-	-	113%	62.5%
Net sales ¹	-	0.951	0.675	-	-	1.37	149.5	546.9
EBITDA	-	-	-	-	-	-	-	-
EBIT ¹	-8.977	-18.05	-20.77	-32.12	-29.52	-38.03	59.54	374.4
Net income ¹	-10.02	-18.06	-31.41	-37.82	-26.56	-35.38	57.12	355
Net Debt	-	-	-	-	-	-	-	-
Reference price ²	20.600	5.400	8.677	7.942	5.770	3.360	3.360	3.360
Nbr of stocks (in thousands)	1,497	1,509	3,475	10,380	21,491	27,855	-	-
Announcement Date	31/03/22	31/03/23	28/03/24	31/03/25	30/03/26	-	-	-

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
UNICYCIVE THERAPEUTICS, INC.	-2.66x	-	-	-	93.59M
WUXI APPTEC CO., LTD.	18.75x	6.69x	13.41x	1.58%	65B
ARGENX SE	27.56x	7.53x	23.83x	0.05%	51.19B
LONZA GROUP AG	35.3x	6.27x	18.74x	0.92%	51.2B
IQVIA HOLDINGS INC.	34.01x	3.32x	14.33x	-.--%	43.93B
BEONE MEDICINES AG	48.9x	5.59x	30.73x	-.--%	41.96B
REVOLUTION MEDICINES, INC.	-18.47x	189.62x	-19.51x	-.--%	38.14B
CELLTRION, INC.	28.97x	8.21x	21.25x	0.37%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	29.19x	6.17x	16.01x	-.--%	25.2B
BIONTECH SE	-13.23x	4.78x	-5.79x	-.--%	22.03B
Average	18.83x	26.46x	12.55x	0.32%	37.2B
Weighted average by Cap.	23.35x	24.98x	14.00x	0.44%